Ethylenediamine-Tetra-Acetic (EDTA) Chelation Therapy for Treatment of Atherosclerosis

EDTA chelation therapy for treatment of atherosclerosis, arteriosclerosis, calcinosis, or similar generalized conditions is not covered by Medicare and is considered experimental. Any use of EDTA for these non–FDA-approved indications is excluded from coverage.

"Ethylenediamine-tetra-acetic acid (EDTA) chelation therapy for treatment of atherosclerosis, arteriosclerosis, calcinosis, or similar generalized conditions not approved by the FDA is not covered a..."

Sign up to see full coverage criteria, indications, and limitations.